AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
Phase 2
Completed
- Conditions
- Persistent or Permanent Non-valvular Atrial Fibrillation
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00623779
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT00622323
- Locations
- 🇵🇭
Research Site, Taytay, Philippines
Seroquel- Agitation Associated With Dementia
Phase 3
Completed
- Conditions
- Alzheimer's DiseaseVascular Dementia
- Interventions
- Drug: Quetiapine FumarateDrug: Placebo
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 333
- Registration Number
- NCT00621647
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT00621361
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00621725
- Locations
- 🇳🇱
Research Site, Rotterdam, Netherlands
Candesartan Effect in Second Stage Arterial Hypertension
Phase 4
Completed
- Conditions
- Stage II Hypertension
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2010-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 214
- Registration Number
- NCT00621153
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
CRESTOR Athero Imaging Head to Head IVUS Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2333
- Registration Number
- NCT00620542
- Locations
- 🇪🇸
Research Site, Alicante, Comunidad Valenciana, Spain
Atacand (Candesartan) Real Life Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14000
- Registration Number
- NCT00620178
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Efficacy and Tolerability of Zolmitriptan Nasal Spray
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2114
- Registration Number
- NCT00617747
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1494
- Registration Number
- NCT00617669
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath